Glaukos Co. (NYSE:GKOS) Given Average Rating of “Moderate Buy” by Brokerages

Glaukos Co. (NYSE:GKOS) has been given an average rating of “Moderate Buy” by the thirteen ratings firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $159.42.

Several research analysts have commented on the company. Stifel Nicolaus boosted their target price on Glaukos from $153.00 to $175.00 and gave the stock a “buy” rating in a research note on Tuesday, December 31st. Truist Financial boosted their target price on Glaukos from $152.00 to $185.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. UBS Group began coverage on Glaukos in a report on Friday, December 6th. They set a “buy” rating and a $182.00 price target on the stock. JPMorgan Chase & Co. boosted their price target on Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Finally, Morgan Stanley cut Glaukos from an “equal weight” rating to an “underweight” rating and set a $120.00 price target on the stock. in a report on Monday, December 2nd.

Insider Activity at Glaukos

In other Glaukos news, insider Tomas Navratil sold 3,416 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $147.14, for a total transaction of $502,630.24. Following the transaction, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. This represents a 4.50 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Gilbert H. Kliman sold 2,000 shares of the stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $144.01, for a total value of $288,020.00. Following the transaction, the director now owns 32,336 shares in the company, valued at $4,656,707.36. The trade was a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,744 shares of company stock worth $2,792,151 over the last ninety days. Insiders own 6.40% of the company’s stock.

Hedge Funds Weigh In On Glaukos

A number of institutional investors and hedge funds have recently modified their holdings of GKOS. Values First Advisors Inc. acquired a new position in shares of Glaukos during the third quarter worth approximately $25,000. IFP Advisors Inc acquired a new position in shares of Glaukos during the fourth quarter worth approximately $43,000. Asset Planning Inc acquired a new position in shares of Glaukos during the fourth quarter worth approximately $90,000. CoreCap Advisors LLC raised its position in shares of Glaukos by 36.4% during the fourth quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier’s stock worth $112,000 after purchasing an additional 200 shares during the period. Finally, Picton Mahoney Asset Management acquired a new position in shares of Glaukos during the fourth quarter worth approximately $125,000. 99.04% of the stock is currently owned by institutional investors.

Glaukos Stock Up 5.5 %

Shares of NYSE GKOS opened at $161.30 on Thursday. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. The company has a market cap of $8.89 billion, a price-to-earnings ratio of -53.41 and a beta of 1.04. Glaukos has a 12 month low of $83.90 and a 12 month high of $163.71. The stock has a 50-day moving average price of $152.65 and a two-hundred day moving average price of $139.03.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.